Corrigendum to 'How I treat medullary thyroid cancer': [ESMO Open Volume 6, Issue 3, June 2021, 100183].
作者信息
Kiesewetter B, Riss P, Scheuba C, Raderer M
机构信息
Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna; European Neuroendocrine Tumor Scoiety (ENETS) Center of Excellence Vienna, Medical University of Vienna.
European Neuroendocrine Tumor Scoiety (ENETS) Center of Excellence Vienna, Medical University of Vienna; Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, Austria.
出版信息
ESMO Open. 2022 Jun;7(3):100516. doi: 10.1016/j.esmoop.2022.100516. Epub 2022 Jun 7.
Abstract
摘要
相似文献
1
Corrigendum to 'How I treat medullary thyroid cancer': [ESMO Open Volume 6, Issue 3, June 2021, 100183].《我如何治疗甲状腺髓样癌》勘误：[《ESMO 开放杂志》第 6 卷，第 3 期，2021 年 6 月，100183]
ESMO Open. 2022 Jun;7(3):100516. doi: 10.1016/j.esmoop.2022.100516. Epub 2022 Jun 7.
2
Corrigendum to 'Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer': [ESMO Open Volume 7 Issue 1 (2022) 100395].《非小细胞肺癌HER2改变检测的共识》勘误：[《ESMO开放杂志》第7卷第1期（2022年）100395]
ESMO Open. 2022 Jun;7(3):100482. doi: 10.1016/j.esmoop.2022.100482. Epub 2022 Apr 21.
3
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078].《肺免疫肿瘤学预后评分（LIPS-3）：对PD-L1≥50%的晚期非小细胞肺癌接受一线帕博利珠单抗治疗患者的预后分类》勘误：[《ESMO Open》第6卷，第2期，2021年4月，100078]
ESMO Open. 2021 Jun;6(3):100137. doi: 10.1016/j.esmoop.2021.100137. Epub 2021 Jun 3.
4
Corrigendum to 'COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)': [ESMO Open Volume 6, Issue 3, June 2021, 100165].《“COVID-19疫情对意大利癌症研究产生重大影响：意大利癌症协会（SIC）的一项调查”》勘误：[《ESMO Open》第6卷，第3期，2021年6月，100165]
ESMO Open. 2021 Aug;6(4):100243. doi: 10.1016/j.esmoop.2021.100243. Epub 2021 Aug 2.
5
Corrigendum to 'Remembering Professor José Baselga': [ESMO Open Volume 6, Issue 3, June 2021, 100121].《缅怀何塞·巴塞尔加教授》勘误：[《ESMO 开放》第 6 卷，第 3 期，2021 年 6 月，100121]
ESMO Open. 2021 Aug;6(4):100221. doi: 10.1016/j.esmoop.2021.100221. Epub 2021 Jul 7.
6
Corrigendum to 'Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Annals of Oncology Volume 31, Issue 6, June 2020, Pages 697-712].《成人急性髓系白血病：ESMO诊断、治疗及随访临床实践指南》勘误：[《肿瘤学年鉴》第31卷，第6期，2020年6月，第697 - 712页]
Ann Oncol. 2021 Jun;32(6):821. doi: 10.1016/j.annonc.2021.04.005. Epub 2021 Apr 20.
7
Corrigendum to 'Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review': [ESMO Open Volume 6, Issue 5, October 2021, 100276].《检查点抑制剂、生育力、妊娠和性生活：一项系统综述》勘误：[《ESMO 开放》第 6 卷，第 5 期，2021 年 10 月，100276]
ESMO Open. 2021 Dec;6(6):100291. doi: 10.1016/j.esmoop.2021.100291. Epub 2021 Oct 13.
8
Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].《新辅助放化疗在手术治疗的Ⅲ期/N2期非小细胞肺癌中优于单纯化疗：一项回顾性单中心队列研究》勘误：[《ESMO Open》第7卷，第2期，2022年4月，100466]
ESMO Open. 2022 Jun;7(3):100523. doi: 10.1016/j.esmoop.2022.100523. Epub 2022 Jun 10.
9
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273].《晚期非小细胞肺癌一线纳武利尤单抗联合伊匹木单抗与2周期化疗对比单纯化疗（4周期）：CheckMate 9LA 2年更新》勘误：[《ESMO Open》第6卷，第5期，2021年10月，100273]
ESMO Open. 2021 Dec;6(6):100345. doi: 10.1016/j.esmoop.2021.100345. Epub 2021 Dec 2.
10
Corrigendum to 'Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study': [ESMO Open Volume 5, Issue 6, 2020, e000985].《ERBB2外显子16跳跃的临床意义：一项真实世界回顾性观察队列研究的分析》勘误：[《ESMO开放》第5卷，第6期，2020年，e000985]
ESMO Open. 2021 Feb;6(1):100052. doi: 10.1016/j.esmoop.2021.100052. Epub 2021 Jan 23.
引用本文的文献
1
LncRNA ZFAS1 promotes invasion of medullary thyroid carcinoma by enhancing EPAS1 expression via miR-214-3p/UCHL1 axis.长链非编码RNA ZFAS1通过miR-214-3p/UCHL1轴增强EPAS1表达促进甲状腺髓样癌的侵袭。
J Cell Commun Signal. 2024 Apr 12;18(2):e12021. doi: 10.1002/ccs3.12021. eCollection 2024 Jun.
Zotero 插件